WS02.2 Aztreonam for inhalation solution (AZLI) for eradication of new onset Pseudomonas aeruginosa (PA) infection in children with cystic fibrosis (CF): Results of facemask vs. nebulizer mouthpiece use

Abstract

Objectives Treating early PA infection in CF often requires giving inhaled antibiotics to very young patients (pts). In the ALPINE study (ClinicalTrials.gov NCT01375049), pts Methods Children age 3 mos to PA infection (first lifetime PA -positive culture [throat swab, sputum, BAL] or PA -positive after ≥2-yr history of PA -negative cultures) were treated with AZLI 75 mg 3x/day for 28 days via a PARI Investigational eFlow® Nebulizer. Recommended delivery was by SmartMask® Baby for pts 3 mos to PA eradication failure rates are presented. Results See the table. No specific safety issues were attributable to either mask or mouthpiece use. PA culture positive at day 28, end of treatment, n/N3 mo to Conclusion In young children with CF, AZLI treatment administered via eFlow nebulizer with SmartMask for initial PA infection had high eradication success rates and should be considered a valid treatment option. No safety issues were associated with specific mask/mouthpiece type. Supported by Gilead Sciences.